Compare DexCom, Inc. (DXCM) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Williams-Sonoma, Inc. — how do they compare? DexCom, Inc. trades at $77.41 (market cap $28.06B), while Williams-Sonoma, Inc. trades at $228.79 (market cap $26.24B). The key difference: DexCom, Inc. and Williams-Sonoma, Inc. are close in size by market cap, and Williams-Sonoma, Inc. pays a 1.36% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | WSM | |
|---|---|---|
Market Cap | $28.06B | $26.24B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $240.06 |
52-Week Low | $54.84 | $165.01 |
Enterprise Value | $27.03B | $27.08B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Williams-Sonoma (WSM) trades at $227.86, up 3.41% with a bullish technical signal. The stock shows strong profitability with a 13.81% net income margin and 54.01% ROE, supported by recent earnings beats. Valuation metrics include a P/E of 24.98 and P/S of 3.45. Recent news highlights brand collaborations and dividend payouts, while cash flow trends indicate operational resilience despite net outflows.
Outlook remains positive with analyst consensus at Buy (28.57%) and a $215.22 price target, though risks include revenue volatility and competitive pressures. The stock's momentum is bolstered by consistent earnings performance, but investors should monitor macroeconomic headwinds affecting discretionary spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
